Innoviva (INVA) Assets Average (2011 - 2026)
Innoviva posted quarterly Assets Average of $1.7 billion for Q1 2026, up 35.86% year-on-year from $1.3 billion in Q1 2025, and up 13.3% on a QoQ basis from $1.5 billion in Q4 2025.
Innoviva (INVA) has 16 years of Assets Average data on file, last reported at $1.7 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 35.86% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 35.86% YoY), and the FY2025 full-year result was $1.5 billion, up 20.99% from the prior year.
- Assets Average for Q1 2026 stood at $1.7 billion, up from $1.5 billion in the prior quarter.
- Across five years, Assets Average topped out at $1.7 billion in Q1 2026 and bottomed at $1.0 billion in Q1 2022.
- The 5-year median for Assets Average is $1.2 billion (2024), against an average of $1.3 billion.
- The widest annual swing landed in 2022, when Assets Average surged 47.06%; it then retreated 6.45% in 2023.
- A 5-year view of Assets Average shows it stood at $1.3 billion in 2022, then decreased by 4.99% to $1.2 billion in 2023, then grew by 4.16% to $1.3 billion in 2024, then grew by 20.99% to $1.5 billion in 2025, then advanced by 13.3% to $1.7 billion in 2026.
- The last three Assets Average figures came in at $1.7 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 1.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.74 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | 1.28 Bn |
| Dec 31, 2024 | 1.27 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.26 Bn |
| Dec 31, 2023 | 1.22 Bn |
| Sep 30, 2023 | 1.15 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.18 Bn |
| Dec 31, 2022 | 1.28 Bn |
| Sep 30, 2022 | 1.23 Bn |
| Jun 30, 2022 | 1.12 Bn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 906.82 Mn |
| Sep 30, 2021 | 838.19 Mn |
| Jun 30, 2021 | 938.72 Mn |
| Mar 31, 2021 | 1.04 Bn |
| Dec 31, 2020 | 960.91 Mn |
| Sep 30, 2020 | 900.94 Mn |
| Jun 30, 2020 | 833.82 Mn |
| Mar 31, 2020 | 756.42 Mn |
| Dec 31, 2019 | 700.39 Mn |
| Sep 30, 2019 | 659.13 Mn |
| Jun 30, 2019 | 616.21 Mn |
| Mar 31, 2019 | 569.15 Mn |
| Dec 31, 2018 | 412.94 Mn |
| Sep 30, 2018 | 308.19 Mn |
| Jun 30, 2018 | 307.72 Mn |
| Mar 31, 2018 | 322.04 Mn |
| Dec 31, 2017 | 379.15 Mn |
| Sep 30, 2017 | 381.50 Mn |
| Jun 30, 2017 | 381.95 Mn |
| Mar 31, 2017 | 385.43 Mn |
| Dec 31, 2016 | 374.77 Mn |
| Sep 30, 2016 | 374.33 Mn |
| Jun 30, 2016 | 382.97 Mn |
| Mar 31, 2016 | 398.38 Mn |
| Dec 31, 2015 | 423.28 Mn |
| Sep 30, 2015 | 449.86 Mn |
| Jun 30, 2015 | 475.39 Mn |
| Mar 31, 2015 | 505.18 Mn |
| Dec 31, 2014 | 537.68 Mn |
| Sep 30, 2014 | 579.66 Mn |
| Jun 30, 2014 | 605.32 Mn |
| Mar 31, 2014 | 643.14 Mn |
| Dec 31, 2013 | 673.64 Mn |
| Sep 30, 2013 | 630.36 Mn |
| Jun 30, 2013 | 593.11 Mn |
| Mar 31, 2013 | 480.05 Mn |
| Dec 31, 2012 | 376.26 Mn |
| Sep 30, 2012 | 391.68 Mn |
| Jun 30, 2012 | 308.57 Mn |
| Mar 31, 2012 | 238.25 Mn |
| Dec 31, 2011 | 271.05 Mn |
| Sep 30, 2011 | 293.22 Mn |